Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised placebo-controlled trial
Top Cited Papers
- 1 March 2021
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 80 (3), 329-338
- https://doi.org/10.1136/annrheumdis-2020-218467
Abstract
Objectives No immunomodulatory drug has been approved for primary Sjogren's syndrome, a systemic autoimmune disease affecting 0.1% of the population. To demonstrate the efficacy of targeting interleukin 6 receptor in patients with Sjogren's syndrome-related systemic complications. Methods Multicentre double-blind randomised placebo-controlled trial between 24 July 2013 and 16 July 2018, with a follow-up of 44 weeks, involving 17 referral centres. Inclusion criteria were primary Sjogren's syndrome according to American European Consensus Group criteria and score >= 5 for the EULAR Sjogren's Syndrome Disease activity Index (ESSDAI, score of systemic complications). Patients were randomised to receive either 6 monthly infusions of tocilizumab or placebo. The primary endpoint was response to treatment at week 24. Response to treatment was defined by the combination of (1) a decrease of at least 3 points in the ESSDAI, (2) no occurrence of moderate or severe activity in any new domain of the ESSDAI and (3) lack of worsening in physician's global assessment on a Visual Numeric Scale >= 1/10, all as compared with enrolment. Results 110 patients were randomised, 55 patients to tocilizumab (mean (SD) age: 50.9 (12.4) years; women: 98.2%) and 55 patients to placebo (54.8 (10.7) years; 90.9%). At 24 weeks, the proportion of patients meeting the primary endpoint was 52.7% (29/55) in the tocilizumab group and 63.6% (35/ 55) in the placebo group, for a difference of - 11.4% (95% credible interval -30.6 to 9.0) (Pr[Toc >Pla]=0.14). Conclusion Among patients with primary Sjogren's syndrome, the use of tocilizumab did not improve systemic involvement and symptoms over 24 weeks of treatment compared with placebo.Keywords
Funding Information
- ROCHE-CHUGAI (N/A)
- Association Française du Gougerot-Sjögren et des Syndromes Secs, AFGS (N/A)
This publication has 36 references indexed in Scilit:
- The Systemic Lupus Erythematosus Responder Index (SRI); A new SLE disease activity assessmentAutoimmunity Reviews, 2012
- EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndromeAnnals Of The Rheumatic Diseases, 2011
- Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity IndexArthritis Care & Research, 2010
- Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2010
- EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndromeAnnals Of The Rheumatic Diseases, 2009
- Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot studyAnnals Of The Rheumatic Diseases, 2008
- Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid‐like structures in Sjögren's syndromeArthritis & Rheumatism, 2005
- Etanercept in Sjögren's syndrome: A twelve‐week randomized, double‐blind, placebo‐controlled pilot clinical trialArthritis & Rheumatism, 2004
- Inefficacy of infliximab in primary Sjögren's syndrome: Results of the randomized, controlled trial of remicade in primary Sjögren's syndrome (TRIPSS)Arthritis & Rheumatism, 2004